Elsevier

The Lancet

Volume 339, Issue 8806, 6 June 1992, Pages 1375-1377
The Lancet

ORIGINAL ARTICLES
Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease

https://doi.org/10.1016/0140-6736(92)91196-FGet rights and content

Abstract

The pathogenesis of Parkinson's disease may be influenced by genetic and environmental factors. Cytochrome P450 mono-oxygenases help to protect against toxic environmental compounds and individual variations in cytochrome P450 expression might, therefore, influence susceptibility to environmentally linked diseases. The frequency of mutant CYP2D6 alleles was studied in 229 patients with Parkinson's disease and 720 controls. Individuals with a metabolic defect in the cytochrome P450 CYP2D6-debrisoquine hydroxylase gene with the poor metaboliser phenotype had a 2·54-fold (95% Cl 1·51-4·28) increased risk of Parkinson's disease. Determination of CYP2D6 phenotype and genotype may help to identify those at greatest risk of Parkinson's disease and may also help to identify the environmental or metabolic agents involved in the pathogenesis of this disease.

References (35)

  • Cr Wolf

    Metabolic factors in cancer susceptibility

    Cancer Surv

    (1990)
  • Lj Golbe

    The genetics of Parkinson's disease

    Neurology

    (1990)
  • Wg Johnson

    Genetic susceptibility to Parkinson's disease

    Neurology

    (1991)
  • Da Price-Evans et al.

    A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population

    J Med Genet

    (1980)
  • Ac Gough et al.

    Identification of the primary gene defect at the cytochrome P450 CYP2D6 locus

    Nature

    (1990)
  • N. Hanioka et al.

    The human CYP2D6 locus associated with a common genetic defect in drug oxidation: a G1943 to A base change in intron 3 of a mutant CYP2D6 allele results in an aberrrant 3' splice recognition site.

    Am J Hum Genet

    (1990)
  • A. Gaedigk et al.

    Deletion of the entire CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism

    Am J Hum Genet

    (1991)
  • Cited by (0)

    View full text